Get the Stockscreener App
57.34
1.55%
-0.8787
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $57.34, with a volume of 6.51M.
It is down -1.55% in the last 24 hours and down -3.83% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$58.22
Open:
$57.65
24h Volume:
6.51M
Relative Volume:
0.52
Market Cap:
$117.04B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
16.10
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
-0.80%
1M Performance:
-3.83%
6M Performance:
+25.72%
1Y Performance:
+13.34%
1-Day Range:
$56.93
$58.00
1-Week Range:
$56.93
$60.78
52-Week Range:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
57.35 | 118.87B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
969.22 | 862.01B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
224.18 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
208.03 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
183.25 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
MRK
Merck Co Inc
|
113.26 | 277.02B | 65.59B | 8.93B | 12.36B | 3.5532 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Varma Mutual Pension Insurance Co Boosts Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
BMO Capital reiterates Bristol-Myers Squibb stock rating at Market Perform - Investing.com Canada
Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™ - Messenger-Inquirer
A Look At Bristol Myers Squibb (BMY) Valuation After Its Q1 2026 Earnings Beat And Reaffirmed Guidance - simplywall.st
Horizon Investments LLC Sells 137,701 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Robertson Stephens Wealth Management LLC Increases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Margin Strength In Q1 2026 Challenges Bearish Earnings Narratives - simplywall.st
Bristol Myers Squibb: The CAR-T Giant The Market Is Undervaluing (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.18% on May 1: Drivers Behind the Movement - TradingKey
Bristol-Myers Loses Venue Fight to Texas in Plavix Litigation - Bloomberg Law News
Big Pharma M&A set for mega year as patent expiries drive deal urgency - Reuters
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2026 Earnings Call Transcript - Insider Monkey
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook - Yahoo Finance
Bristol-Myers Squibb Co (BMY) Q1 2026 Earnings Call Highlights: - GuruFocus
Is Bristol Myers Squibb (BMY) Still Attractively Priced After Its Strong 1 Year Share Price Gain - simplywall.st
BMS brings the buzz around late-stage readouts amid a so-so Q1 - Pharmaceutical Technology
BMO raises Bristol-Myers Squibb stock price target on Eliquis beat - Investing.com Canada
BMY Stock Price, Quote & Chart | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
SIIT U.S. Managed Volatility Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
LSV VALUE EQUITY FUND's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb (NYSE:BMY) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS - MarketBeat
Is Bristol-Myers Squibb Co (BMY) Overvalued After 5.2% Rally? GF - GuruFocus
Bristol-Myers Squibb (BMY) Reports Solid Q1 2026 Results with Po - GuruFocus
MSN Money - MSN
Why Bristol Myers Squibb Stock Rocked the Market Today - The Motley Fool
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Why Bristol Myers Squibb Stock Rocked the Market Today - The Motley Fool
Why Is Bristol-Myers Squibb Stock Trading Higher On Thursday? - Benzinga
Bristol Myers (BMY) Q1 2026 Earnings Transcript - The Motley Fool
INTECH INVESTMENT MANAGEMENT LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales By Reuters - Investing.com
Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales - Reuters
Bristol Myers Squibb Surpasses Profit Expectations: Eliquis and Cancer Medicines Drive Growth - Devdiscourse
PUTNAM GLOBAL HEALTH CARE FUND's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb jumps after Q1 results and reaffirmed 2026 outlook - Quiver Quantitative
Bristol Myers Q1 2026 slides: growth portfolio drives revenue beat - Investing.com
Bristol Myers Squibb Company $BMY Shares Sold by Verity Asset Management Inc. - MarketBeat
Crohn’s Disease Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd - Barchart.com
Bristol Myers (BMY) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance UK
Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales - WNWN-FM
Bristol-Myers Squibb (BMY) Reports Strong Q1 2026 Earnings, Beats Expectations - GuruFocus
BMS beats estimates and reaffirms guidance - The Pharma Letter
Bristol Myers Squibb (BMY) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance UK
Bristol Myers Squibb (NYSE:BMY) Q1 2026 Earnings Beat Driven by Growth Portfolio - ChartMill
Krazati's colorectal cancer approval in jeopardy | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Bristol Myers Squibb (BMY) Q1 2026: EPS $1.31 Beats $1.19 Est., - GuruFocus
Bristol Myers Squibb (NYSE:BMY) Updates FY 2026 Earnings Guidance - MarketBeat
Bristol-Myers Squibb Company Stock (US0897961004): Q1 Revenues Rise 3% to $11.5 Billion - AD HOC NEWS
BRISTOL-MYERS SQUIBB ($BMY) Releases Q1 2026 Earnings - Quiver Quantitative
EDGAR Filing Documents for 0000014272-26-000008 - SEC.gov
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):